---
title: "Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295645480.md"
description: "Natera has partnered with Kupando Therapeutics to utilize its Latitude ctDNA test in a Phase 1 trial for immunotherapy candidate KUP-101. The assay will monitor serial ctDNA dynamics to assess treatment response in advanced skin cancers across multiple clinical sites, including centers in Germany."
datetime: "2026-08-12T10:01:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295645480.md)
  - [en](https://longbridge.com/en/news/295645480.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295645480.md)
generator: "portal-rs"
---

# Natera partners with Kupando Therapeutics to use Latitude ctDNA test in Phase 1 skin cancer trial

-   Natera entered a collaboration with Kupando Therapeutics to support a Phase 1 trial of immunotherapy candidate KUP-101. \* Latitude, Natera’s tissue-free MRD assay, will track serial ctDNA dynamics to monitor treatment response in advanced skin cancers. \* Testing will be conducted at multiple timepoints as patients receive KUP-101 across activated clinical sites, including oncology centers in Germany. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260812873623) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NTRA.US](https://longbridge.com/en/quote/NTRA.US.md)

## Related News & Research

- [Natera CEO Steven Leonard Chapman disposes of 1,698 common shares for $545,441.02](https://longbridge.com/en/news/297973461.md)
- [Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?](https://longbridge.com/en/news/297400181.md)
- [New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma | NTRA Stock News](https://longbridge.com/en/news/297636654.md)
- [Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer | NTRA Stock News](https://longbridge.com/en/news/297346091.md)
- [Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™ | NTRA Stock News](https://longbridge.com/en/news/297164196.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**